Auszug
Größte Gruppe der Antiallergika sind die wenig sedierenden H1-Antihistaminika, die vor allem zur Behandlung des Heuschnupfens, der allergischen Bindehautentzündung und der Urtikaria eingesetzt werden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abramson M, Puy R, Weiner J (2003):Allergen immunotherapy for asthma (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
Adkinson NF, Eggleston PA, Eney D, Goldstein EO, Schuberth KC et al. (1997): A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336: 324–331.
Arvidsson MB, Löwhagen O, Rak S (2002): Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 109: 777–783.
Austen KF (2001): Allergies, anaphylaxis, and systemic mastocytosis. In: Braunwald E et al. (eds): Harrison’s principles of internal medicine. McGraw-Hill Medical Publishing Division, New York, pp.1913–1922.
Bousquet J, Hejjaoui A, Clauzel AM, Guerin B, Dhivert H, Skassa-Brociek W, Wichel FB (1988): Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 82: 971–977.
Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB et al. (1999): Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54: 249–260.
Bundesministerium für Gesundheit und Soziale Sicherung (2006): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie in Abschnitt F: „OTC-Übersicht“ vom 15. November 2005. BAnz. Nr. 41 (S. 1275) vom 28.02.2006.
Canonica GW, Passalacqua G (2003): Noninjection routes for immunotherapy. J Allerg Clin Immunol 111: 437–448.
Deutsche Gesellschaft Allergologie und klinische Immunologie (2006): Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 15: 56–74. Im Internet: www.leitlinien.net
Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brian F, Noble W et al. (1999): Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341: 468–475.
Fricke U. Klaus W. (2003): Neue Arzneimittel, Band 13 Fakten und Bewertungen von 1998 bis 2001 zugelassenen Arzneimitteln. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
Fricke U, Schwabe U (2004): Neue Arzneimittel. In Schwabe U, Paffrath D (Hrsg): Arzneiverordnungs-Report 2003. Springer-Verlag, Berlin Heidelberg, S. 24–87.
Gemeinsamer Bundesausschuss (2005): Gemeinsamer Bundesausschuss schlägt Erweiterung der OTC-Liste vor. Pressemitteilung vom 19. Juli 2005. Im Internet aufgesucht am 28.07.2005 unter: www.g-ba.de/cms/upload/pdf/abs5/pm/2005-07-19-OTC-Enteral-PM.pdf
Golden DB (2005): Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 115: 439–47.
Guez S, Vatrinet C, Fadel R, Andre C (2000): House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 55: 369–375.
Hoff M, Krail M, Kästner M, Haustein D, Vieths S (2002): Fusarium culmorum causes strong degradation of pollen allergens in extract mixtures. J Allergy Clin Immunol 109: 96–101.
Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM (1978): A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 299: 157–161.
Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D (2001): Neubewertung des Risikos von Test-und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesunheitsbl — Gesundheitsforsch — Gesundheitsschutz 44: 709–718.
Mellerup MT, Hahn GW, Poulsen LK, Malling HJ (2000): Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 30: 1423–1429.
Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L et al. (2002): Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 109: 251–256.
Moffitt JE, Golden DB, Reisman RE, Lee R, Nicklas R, Freeman T, deshazo R, Tracy J, Bernstein IL, Blessing-Moore J, Khan DA, Lang DM, Portnoy JM, Schuller DE, Spector SL, Tilles SA (2004): Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 114: 869–886.
Olsen OT, Larsen KR, Jacobsan L, Svedsen UG (1997): A 1-year placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 52: 853–859.
O’Neill SM, Forsyth A (1988): Urticaria. Prescribers J 28: 14–20.
Petersen BN, Janniche H, Munch EP, Wihl JA, Bowadt H, Ipsen H, Lowenstein H (1988): Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 43: 353–362.
Pichler CE, Helbling A, Pichler WJ (2001): Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56: 301–306.
Pichler CE, Marquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ (1997): Specific immunotherapy with Dermatophagoides ptheronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52: 274–283.
Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA (1993): Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 92: 6–15.
Ring J, Fuchs T, Schultze-Werminghaus G (Hrsg.) (2004) DGAI, ÄDA, DAAU: Weißbuch Allergie in Deutschland, 2. Aufl. Urban und Vogel München.
Routledge PA, Lindquist M, Edwards IR (1999): Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy 29(Suppl 3): 240–246.
Ruëff F, Wenderoth A, Przybilla B (2001): Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108: 1027–1032.
Sennekamp J, Fuchs Th, Hornung B., Kersten W, Klimek L, Leupold W, Merk H, Rebien W, Schultze-Wenninhaus G (2002): Empfehlungen zur praktischen Durchführung der spezifischen Immuntherapie mit Allergenen. Allergo J 11:332–338.
Spencer CM, Faulds D, Peters DH (1993): Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 46: 1055–1080.
Warner JO, Price JF, Soothill JF, Hey EN (1978): Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2: 912–915.
WHO Position Paper (1998): Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl 1): 1–42.
Wilson DR, Lima MT, Durham SR (2005): Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60: 4–12.
Wilson DR, Torres LI, Durham SR (2003): Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Zawinell, A., Schwabe, U. (2007). Antiallergika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-540-34370-7_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-34369-1
Online ISBN: 978-3-540-34370-7
eBook Packages: Medicine (German Language)